Visual Abstract
Objective: To investigate the effect of 6m CFTR modulators treatment on insulin secretion in CF patients.
Methods: 21 CF patients (17 Phe.508del hom) were included in a prospective, observational study. After 6m of lumacaftor/tezacaftor+ivacaftor, AUC of glucose, insulin and C peptide were evaluated by using 5-point OGTT. GLM repeated measures test performed.
Results: 21 patients initially participated, 3 were excluded: 1 had no basal OTTG, and 2 had drug intolerance. Median age 14,7yr (ICR 8,5-26,0); 57% ≥13 yr and 57% male. Initially: 8 had normal glucose metabolism (N), 1 indeterminate (IND), 2 abnormal glucose tolerance (AGT), 2 IND+AGT, and 5 CFRD. After 6m: in the N group: 5 (62,5%; 100% <18yr) worsened their glucose tolerance status and 3 (37,5%) had no group change; in the abnormal glucose group: 2 (20%) worsened their glucose tolerance status (100% <18 yr), 3 (30%) improved (66,6% adults) and 5 (50%) remained similar (60% adults). Significant increase in AUC of glucose, insulin and C-peptide were observed after 6m in the whole group, without differences after adjustment for glucose tolerance status subgroup in AUC of insulin and C-peptide (Table 1).
Conclusion: Increase in AUC of insulin and C-peptide were observed after 6m with CFTR modulators, suggesting a potential role in improving insulin secretion. AUC of glucose should be analyzed prospectively.
E. Lecumberri: None. R. Y. Yelmo: None. M. Garriga: None. A. F. Lamas: None. S. Vicente: Consultant; Self; Abbott, Fresenius Medical Care, Mead Johnson Nutrition. M. Martin-frias: None. L. Nattero-chávez: None. V. Martínez-vaello: None. L. Maiz: None. C. Sánchez rodríguez: None. M. Lorenzo: None. B. Dorado avendaño: None.
